Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly FCF Margin of 880.53% in Q3 2021, up 106.86% quarter-over-quarter from 12835.99% in Q2 2021, and up 309972.0% on a YoY basis from N/an in Q3 2020.
Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 880.53% for Q3 2021.
- In Q3 2021, FCF Margin rose 309972.0% year-over-year to 880.53%; the TTM figure through Jun 2022 stood at 32631.18% (down 3036082.0% YoY), while the FY2021 annual figure was 5470.98%, down 346757.0% from the prior year.
- FCF Margin was 880.53% for Q3 2021 at Corbus Pharmaceuticals Holdings, up from 12835.99% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 880.53% in Q3 2021 to a low of 12835.99% in Q2 2021.
- Historically, FCF Margin has averaged 2286.68% across 5 years, with a median of 808.56% in 2017.
- The sharpest annual moves came in 2019 and 2020: FCF Margin surged 703513 bps in 2019, then slumped 924062 bps in 2020.
- A 5-year view of FCF Margin shows it stood at 800.85% in 2017, then slumped by 768 bps to 6951.64% in 2018, then soared by 101 bps to 83.49% in 2019, then plunged by 1365 bps to 1055.93% in 2020, then surged by 183 bps to 880.53% in 2021.
- The last three FCF Margin figures came in at 880.53% (Q3 2021), 12835.99% (Q2 2021), and 3366.58% (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 880.53% |
| Jun 30, 2021 | -12,835.99% |
| Mar 31, 2021 | -3,366.58% |
| Dec 31, 2020 | -1,055.93% |
| Sep 30, 2020 | -2,219.20% |
| Jun 30, 2020 | -9,297.60% |
| Mar 31, 2020 | -1,592.73% |
| Dec 31, 2019 | 83.49% |
| Sep 30, 2019 | -705.89% |
| Jun 30, 2019 | -56.98% |
| Mar 31, 2019 | 543.51% |
| Dec 31, 2018 | -6,951.64% |
| Sep 30, 2018 | -816.27% |
| Jun 30, 2018 | -506.31% |
| Mar 31, 2018 | -301.86% |
| Sep 30, 2017 | -800.85% |
| Jun 30, 2017 | -1,643.80% |
| Mar 31, 2017 | -516.06% |
| Sep 30, 2016 | -420.29% |
| Jun 30, 2016 | -655.84% |